AMG 172 First in Human Study in Patients With Kidney Cancer
A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Villejuif, France, 94805
- Research Site
-
-
-
-
-
Heidelberg, Germany, 69120
- Research Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Research Site
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must have a pathologically documented, definitively diagnosed, clear cell RCC that is relapsed/refractory following at least two lines of systemic therapy (one of which must be a tyrosine kinase), or the subject refuses standard therapy
- Measurable disease per RECIST 1.1 criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part 1 of the study.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
- Willing to provide tumor samples and / or slides
Hematological function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;
- Platelet count ≥ 100 x 10^9/L;
- Hemoglobin > 9 g/dL
- Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x institutional upper limit of normal (IULN)
Hepatic function, as follows:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN;
- Total bilirubin < 1.5 x ULN (< 3.0 x ULN for subjects with documented Gilbert's Disease or for whom the indirect bilirubin level suggests an extrahepatic source of elevation);
- Alkaline phosphatase < 2 x ULN (< 5 x ULN in subjects whom the PI and sponsor agree that clinical data suggest extrahepatic source of elevation)
- Other inclusion criteria may apply
Exclusion Criteria:
- Known primary central nervous system (CNS) tumors or brain metastases
- History of bleeding diathesis
- Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication, or uncontrolled hypertension in the opinion of the investigator
- Clinically significant ECG changes which obscure the ability to assess the PR, QT, and QRS interval; congenital long QT syndrome
- A baseline ECG QTcF > 470 msec
- Known positive test for human immunodeficiency virus (HIV)
- Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
- Other exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose exploration
Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks.
Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
|
AMG 172 is an antibody drug conjugate
|
|
Experimental: Dose expansion
Dose and dosing frequency selected from Part 1 dose exploration.
|
AMG 172 is an antibody drug conjugate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinically significant or ≥ Grade 3 CTCAE changes in safety laboratory tests, physical examinations, ECGs, or vital signs
Time Frame: 28 days after the last subject enrolled of each cohort in Part 1 and every 10 subjects enrolled in Part 2 (if available)
|
28 days after the last subject enrolled of each cohort in Part 1 and every 10 subjects enrolled in Part 2 (if available)
|
|
PK parameters including but not limited to, maximum observed concentration (Cmax), area under the concentration-time curve (AUC) and half life (t1/2)
Time Frame: 12 time points up to 8 weeks
|
12 time points up to 8 weeks
|
|
Objective response rate for subjects treated at MTD based on RECIST 1.1
Time Frame: 3 years
|
3 years
|
|
The MTD for at least one of two dosing schedules: every two weeks or every three weeks
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Development of human anti-human antibody against AMG 172
Time Frame: 1 year
|
1 year
|
|
Objective response rate for subjects not treated at MTD based on RECIST 1.1
Time Frame: 3 years
|
3 years
|
|
Clinical benefit as measured by duration of response per RECIST 1.1
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20090515
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.